1. Home
  2. BNZI vs KPRX Comparison

BNZI vs KPRX Comparison

Compare BNZI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banzai International Inc.

BNZI

Banzai International Inc.

HOLD

Current Price

$1.23

Market Cap

9.6M

Sector

N/A

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.08

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNZI
KPRX
Founded
2016
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
9.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNZI
KPRX
Price
$1.23
$2.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$30.00
$10.00
AVG Volume (30 Days)
537.6K
51.8K
Earning Date
11-14-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,650,176.00
N/A
Revenue This Year
$223.24
N/A
Revenue Next Year
$31.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.06
N/A
52 Week Low
$1.09
$1.77
52 Week High
$27.00
$4.18

Technical Indicators

Market Signals
Indicator
BNZI
KPRX
Relative Strength Index (RSI) 37.37 47.60
Support Level $1.14 $2.00
Resistance Level $1.40 $2.17
Average True Range (ATR) 0.15 0.13
MACD 0.04 0.04
Stochastic Oscillator 31.83 77.81

Price Performance

Historical Comparison
BNZI
KPRX

About BNZI Banzai International Inc.

Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: